Amedisys (AMED) Competitors

Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.

Which has more volatility and risk, AMED or DVA?

Amedisys has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in AMED or DVA?

94.4% of Amedisys shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 2.1% of Amedisys shares are held by insiders. Comparatively, 2.0% of DaVita shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor AMED or DVA?

DaVita received 2 more outperform votes than Amedisys when rated by MarketBeat users. Likewise, 61.13% of users gave DaVita an outperform vote while only 58.58% of users gave Amedisys an outperform vote.

Company	Underperform	Outperform
Amedisys	Outperform Votes 495 58.58%	Underperform Votes 350 41.42%
DaVita	Outperform Votes 497 61.13%	Underperform Votes 316 38.87%

Which has stronger earnings & valuation, AMED or DVA?

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amedisys	$2.35B	1.28	-$9.75M	$1.31	69.91
DaVita	$12.82B	0.91	$936.34M	$10.74	13.60

Does the media refer more to AMED or DVA?

In the previous week, DaVita had 17 more articles in the media than Amedisys. MarketBeat recorded 26 mentions for DaVita and 9 mentions for Amedisys. Amedisys' average media sentiment score of 1.30 beat DaVita's score of 1.09 indicating that Amedisys is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amedisys	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	15 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend AMED or DVA?

Amedisys presently has a consensus price target of $101.00, suggesting a potential upside of 10.29%. DaVita has a consensus price target of $166.33, suggesting a potential upside of 13.84%. Given DaVita's higher probable upside, analysts plainly believe DaVita is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amedisys	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DaVita	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is AMED or DVA more profitable?

DaVita has a net margin of 7.31% compared to Amedisys' net margin of 3.57%. DaVita's return on equity of 115.48% beat Amedisys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amedisys	3.57%	12.20%	6.74%
DaVita	7.31%	115.48%	4.94%

Summary

DaVita beats Amedisys on 11 of the 17 factors compared between the two stocks.